



# Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2021-2022 vs 2019-2020 (FPN 1878P)

Jet Ankersmid-Matos Miguel <sup>1</sup>, Nathalie van Veen <sup>1</sup>, Wouter Jacobs <sup>2</sup>, Ronald Damhuis <sup>3</sup>, Cornelia van Uden-Kraan <sup>1</sup>, Ewoudt van de Garde <sup>4,5</sup>, on behalf of the Santeon VBHC Lung Cancer Research Group

<sup>1</sup>Santeon, the Netherlands, <sup>2</sup>Martini Hospital Groningen, the Netherlands, <sup>3</sup>Netherlands Comprehensive Cancer Organisation (IKNL), the Netherlands, <sup>4</sup>St. Antonius Hospital Nieuwegein/Utrecht, the Netherlands, <sup>5</sup>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands

## Introduction

- A recently published study provided overview of real-world treatment patterns and outcomes for patients diagnosed with metastatic non-small cell lung cancer in the Netherlands in 2019 and 2020.
- This study provides an update using data from patients diagnosed 2021 and 2022.

Scan this QR-code for the paper about the 2019-2020 data:




## Results

	2019-2020 	2021-2022 
<b>N All hospitals</b>	9511	9354
<b>N Santeon</b>	1169	1126
<b>Treatment characteristics</b>		
Chemotherapy	1219 (13%)	771 (8%)
Immunotherapy	1262 (13%)	1196 (13%)
Chemo-immunotherapy	2474 (26%)	3150 (34%)
Best supportive care	4485 (47%)	4198 (45%)
Unknown	71 (1%)	39 (0%)
<b>Survival</b>		
One-year survival	2975 (31%)	2948 (32%)
Two-year survival	1883 (20%)	1864 (20%)
<b>Intermediate outcomes (Santeon)</b>		
Early discontinuation chemotherapy	144/391 (37%)	177/434 (41%)
Dose adjustments or switch chemotherapy	68/391 (17%)	91/434 (21%)
Immunotherapy pause	18/156 (12%)	39/554 (7%)

## Methods

Analysis data 2021-2022 Dutch National Cancer Registry (NCR):

- Treatment patterns
- Survival



Deep-dive analysis data 2021-2022 Santeon\*:

- Early discontinuation
- Dose adjustments
- Immunotherapy pause



Comparison with 2019-2020 cohort



\*Santeon is a collaborative network of seven Dutch top-clinical hospitals that, based on the principles of Value-Based Health Care, work together to continuously improve healthcare quality, outcomes, and efficiency through shared learning and data-driven innovation.

Interested in the Patients-Like-Me module that was developed based on this data? Scan this QR code:



## Conclusions

- Treatment practices and outcomes remained similar, with a notable shift from chemotherapy to chemo-immunotherapy. Early discontinuation, dose adjustments and chemotherapy switches increased slightly.
- It is important to discuss real-world outcome data with patients to support shared decision-making about treatment.